{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:12:39Z","timestamp":1788300759900,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008510","name":"University of Maryland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019823","name":"University of Maryland, Baltimore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["DB-2020C2-20306"],"award-info":[{"award-number":["DB-2020C2-20306"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eprac.2025.09.004","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:03:49Z","timestamp":1757649829000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk"],"prefix":"10.1016","volume":"32","author":[{"given":"Urja N.","family":"Kalathiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya Sindu","family":"Swarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy M.","family":"Mickelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2025.09.004_bib1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12876-021-01906-2","article-title":"The global, regional, and national burden of acute pancreatitis in 204 countries and territories, 1990\u20132019","volume":"21","author":"li","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.004_bib3","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/dc08-1755","article-title":"Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study","volume":"32","author":"Noel","year":"2009","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2025.09.004_bib4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1463-1326.2012.01667.x","article-title":"Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk","volume":"14","author":"Brodovicz","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.004_bib5","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1097\/MS9.0000000000002036","article-title":"Bidirectional relationship between pancreatic cancer and diabetes mellitus: a comprehensive literature review","volume":"86","author":"Sapoor","year":"2024","journal-title":"Ann Med Surg 2012"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.004_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/biomedicines11030667","article-title":"The cause and effect relationship of diabetes after acute pancreatitis","volume":"11","author":"\u015aliwi\u0144ska-Mosso\u0144","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.eprac.2025.09.004_bib7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-4598-2-4","article-title":"The relationship between diabetes and pancreatic cancer","volume":"2","author":"Wang","year":"2003","journal-title":"Mol Cancer"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2025.09.004_bib8","first-page":"S158","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.004_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s44161-024-00453-9","article-title":"Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk","volume":"3","author":"McCoy","year":"2024","journal-title":"Nat Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.eprac.2025.09.004_bib10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2215\/CJN.0000000587","article-title":"Kidney outcomes with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas in type 2 diabetes and moderate cardiovascular risk","volume":"20","author":"Neumiller","year":"2024","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.004_bib11","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3390\/cancers16091625","article-title":"The use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus does not increase the risk of pancreatic cancer: a U.S.-based cohort study","volume":"16","author":"Ayoub","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.004_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50408","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes","volume":"7","author":"Dankner","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.004_bib13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eprac.2021.12.007","article-title":"Comparison of new glucose-lowering drugs on the risk of pancreatitis in type 2 diabetes: a network meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.004_bib14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/dom.12926","article-title":"Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials","volume":"19","author":"Monami","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.09.004_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/pds.4943","article-title":"Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"29","author":"Tang","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.004_bib16","first-page":"602","article-title":"Diabetes mellitus and the risk of pancreatitis: A systematic review and meta-analysis of cohort studies","volume":"20","author":"Aune","year":"2020","journal-title":"Pancreatol Off J Int Assoc Pancreatol IAP Al"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.004_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100852","article-title":"Derivation of an annualized claims-based major adverse cardiovascular event estimator in type 2 diabetes","volume":"3","author":"McCoy","year":"2024","journal-title":"JACC Adv"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.004_bib18","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.eprac.2025.09.004_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff Proj Hope"},{"key":"10.1016\/j.eprac.2025.09.004_bib20","doi-asserted-by":"crossref","unstructured":"Polley E, LeDell E, Kennedy C, Van Der Laan M. SuperLearner: Super Learner Prediction. Published online September 27, 2011:2.0-29. https:\/\/doi.org\/10.32614\/CRAN.package.SuperLearner","DOI":"10.32614\/CRAN.package.SuperLearner"},{"issue":"19","key":"10.1016\/j.eprac.2025.09.004_bib21","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.eprac.2025.09.004_bib22","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1309","article-title":"Super learner","volume":"6","author":"van der Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.004_bib23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiol Camb Mass"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.004_bib24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.004_bib25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.eprac.2025.09.004_bib26","author":"Moore"},{"issue":"17","key":"10.1016\/j.eprac.2025.09.004_bib27","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/sim.7297","article-title":"Causal inference in survival analysis using pseudo-observations","volume":"36","author":"Andersen","year":"2017","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.09.004_bib28","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/sim.9681","article-title":"A comparison of different methods to adjust survival curves for confounders","volume":"42","author":"Denz","year":"2023","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.004_bib29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/14740338.2023.2284992","article-title":"Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Muhammed","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.004_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: a systematic review and meta-analysis","volume":"17","author":"Nagendra","year":"2023","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"10.1016\/j.eprac.2025.09.004_bib31","article-title":"Safety of Semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2025.09.004_bib32","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.2337\/dc19-1350","article-title":"Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial","volume":"43","author":"Jabbour","year":"2020","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.004_bib33","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.004_bib34","first-page":"969","article-title":"Glucagon-like peptide 1 receptor agonist (GLP1RA) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies","volume":"12","author":"Caparrotta","year":"2021","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"issue":"35","key":"10.1016\/j.eprac.2025.09.004_bib35","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehaa082","article-title":"Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials","volume":"41","author":"Marsico","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.eprac.2025.09.004_bib36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.004_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3061","article-title":"No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: a pooled analysis of cardiovascular outcome trials","volume":"34","author":"Liu","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.004_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12933-017-0512-z","article-title":"Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes","volume":"16","author":"Zhang","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.004_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1021\/acs.biochem.9b00692","article-title":"Structural insights into the inhibitory mechanism of insulin secretagogues on the pancreatic ATP-sensitive potassium channel","volume":"59","author":"Wu","year":"2020","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.004_bib41","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000621","article-title":"Drug-induced acute pancreatitis: an evidence-based classification (revised)","volume":"14","author":"Saini","year":"2023","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.004_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.004_bib43","first-page":"206","article-title":"Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis","volume":"6","author":"Mart\u00ednez","year":"2006","journal-title":"Pancreatol Off J Int Assoc Pancreatol IAP Al"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25010213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25010213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:15:18Z","timestamp":1778616918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25010213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1530891X25010213"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.09.004","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Risk of Adverse Pancreatic Events With GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas Among Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}